Compare · NMRA vs RVMD
NMRA vs RVMD
Side-by-side comparison of Neumora Therapeutics Inc. (NMRA) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NMRA and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $31.57B, about 105.2x NMRA ($300.2M).
- Over the past year, NMRA is up 51.8% and RVMD is up 265.3% - RVMD leads by 213.4 points.
- NMRA has been more active in the news (6 items in the past 4 weeks vs 5 for RVMD).
- RVMD has more recent analyst coverage (25 ratings vs 21 for NMRA).
- Company
- Neumora Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- $1.66+2.80%
- $148.08-0.27%
- Market cap
- $300.2M
- $31.57B
- 1M return
- -8.82%
- +4.56%
- 1Y return
- +51.83%
- +265.28%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2020
- News (4w)
- 6
- 5
- Recent ratings
- 21
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest NMRA
- SEC Form 4 filed by Director Burow Kristina
- SEC Form 4 filed by Director Fust Matthew K
- SEC Form 4 filed by Director Piacquad David
- SEC Form 4 filed by Director Halawa Alaa
- SEC Form 4 filed by Director Ho Maykin
- SEC Form 8-K filed by Neumora Therapeutics Inc.
- Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
- SEC Form 10-Q filed by Neumora Therapeutics Inc.
- Neumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Latest RVMD
- Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
- Officer Mancini Anthony exercised 3,121 shares at a strike of $33.62 and sold $480,611 worth of shares (3,121 units at $153.99) as part of a pre-agreed trading plan (SEC Form 4)
- Bernstein initiated coverage on Revolution Medicines with a new price target
- Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
- Truist resumed coverage on Revolution Medicines with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress